Pfizer preps animal health IPO; Value-based pricing stirs anxiety among drug companies;

 @FierceBiotech: Catalent continues restructuring efforts as it completes work on NC fill-finish plant. News | Follow @FierceBiotech

 @RyanMFierce: My post about how Lilly leads docs to cancer drug trials with iPad app. Article | Follow @RyanMFierce

> Pfizer ($PFE) is prepping registration documents for an animal-health IPO. The company would offer a minority stake in the unit, dubbed Zoetis, as a step toward spinning off the unit completely. It's the latest update on Pfizer's efforts to refocus on its "innovative core." Report

> The U.K.'s move to a "value-based" pricing strategy for therapeutics is causing some deep anxiety among drug companies, which believe it could seriously undermine drug innovation in the country. Story

> The Ontario Institute for Cancer Research is providing $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin lymphoma. Release

Pharma News

 @FiercePharma: Pfizer plans IPO for minority stake in animal-health unit--dubbed "Zoetis"--on its way to total spinoff. Report | Follow @FiercePharma

> Pharma feeds multiply on Twitter. Story

> Lilly chief skeptical of buyouts--and not just megadeals. Article

> Will Horizant's new use soothe tempers at XenoPort, GSK? More

> Novartis yanks mispackaged birth-control pills. News

Medical Devices News

 @FierceMedDev: Only a few weeks left to submit your nominations for the 15 fiercest private device developers. Survey | Follow @FierceMedDev

> Device tax repeal up for House vote today as White House threatens veto. Item

> Mindray snaps up Chinese orthopedics maker for $35.5M. Story

> Report: Panasonic to become major Olympus shareholder with $635M investment. More

CRO News

 @NesaNFierce: Catalent's renovated fill-finish plant in NC is more in-tune with the company's renewed business focus. Article | Follow @NesaNFierce

> Siegfried buys Allied Medical Products for $58M. News

> Medtox's toxicology offerings contribute to LabCorp acquisition, as contract manufacturing shrinks. More

> WuXi PharmaTech speaks out on compound theft by former employee. Article

> Kansas City CROs form alliance to attract outsourcing work to region. Item

Pharma Manufacturing News

> FDA commish suggests drugmakers get on board with track and trace. More

> Sandoz recalls Introvale contraceptives. News

> Indian API maker looks to Asia for cheap energy. Report

Vaccines News

> NewLink Genetics takes the stage at ASCO. Story

> Vax, hormone combo could up efficacy in prostate cancer. Article

> Mapping the way to a Candida vaccine. Item

> Affiris' Parkinson's therapeutic vax starts clinical trials. More

And Finally... Researchers at Mount Sinai say they have been working on a new therapy that has the potential to treat multiple tumors. And they say it could offer a whole new approach to cancer drug discovery. Release

Suggested Articles

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.